Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis has completed the submission of new drug application (NDA) for cabozantinib as a treatment for progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) patients, with the FDA.
Subscribe to our email newsletter
Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET.
As a part of the NDA filing, which is based on data from a Phase III pivotal trial in patients with advanced MTC, Exelixis has requested Priority Review designation from the FDA.
The EXAM trial with progression-free survival (PFS) as the primary endpoint was conducted under a Special Protocol Assessment with the FDA.
In October 2011, the company announced top-line results from the trial that met its primary endpoint of improving PFS: compared with placebo, cabozantinib improved median PFS by 7.2 months.